3-Amino-3-[3-(4-methylphenoxy)phenyl]propanoic acid;hydrochloride

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 3-Amino-3-[3-(4-methylphenoxy)phenyl]propanoic acid;hydrochloride
• 化学式: C16H18ClNO3
• 分子量: 307.77
• InChiKey: AHNKHYNKJOKSDP-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.68
• 重原子数：
  21
• 可旋转键数：
  5
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.19
• 拓扑面积：
  72.6
• 氢给体数：
  3
• 氢受体数：
  4

文献信息

• Propionic Acid Derivatives and Methods of Use Thereof
  申请人：Biediger Ronald J.

  公开号：US20180312498A1

  公开（公告）日：2018-11-01

  Provided herein are compounds and pharmaceutical compositions of formula I where R 1 , R 2 , R 3 , R 4 , R 5 , X and R 6 are as described herein. Also provided pharmaceutically acceptable salts or stereoisomer(s) of these compounds. In addition methods are provided for antagonizing the action of an α4-integrin to treat various pathophysiological conditions.

  本文提供了化合物和制药组合物的公式I，其中R1、R2、R3、R4、R5、X和R6如本文所述。还提供了这些化合物的药用可接受盐或立体异构体。此外，还提供了拮抗α4整合素作用以治疗各种病理生理条件的方法。
• Propionic acid derivatives and methods of use thereof
  申请人：Biediger Ronald J.

  公开号：US10246451B2

  公开（公告）日：2019-04-02

  Provided herein are compounds and pharmaceutical compositions of formula I where R1, R2, R3, R4, R5, X and R6 are as described herein. Also provided pharmaceutically acceptable salts or stereoisomer(s) of these compounds. In addition methods are provided for antagonizing the action of an α4-integrin to treat various pathophysiological conditions.

  本文提供了式 I 的化合物和药物组合物 其中 R1、R2、R3、R4、R5、X 和 R6 如本文所述。还提供了这些化合物的药学上可接受的盐或立体异构体。此外，还提供了拮抗α4-整合素作用以治疗各种病理生理状况的方法。
• PROPIONIC ACID DERIVATIVES AND METHODS OF USE THEREOF
  申请人：Aviara Pharmaceuticals, Inc.

  公开号：EP3615515A2

  公开（公告）日：2020-03-04
• [EN] PROPIONIC ACID DERIVATIVES AND METHODS OF USE THEREOF<br/>[FR] DÉRIVÉS D'ACIDE PROPIONIQUE ET MÉTHODES D'UTILISATION ASSOCIÉES
  申请人：AVIARA PHARMACEUTICALS INC

  公开号：WO2018209363A2

  公开（公告）日：2018-11-15

  Provided herein are compounds and pharmaceutical compositions of formula I where R1, R2, R3, R4, R5, X and R6 are as described herein. Also provided pharmaceutically acceptable salts or stereoisomer(s) of these compounds. In addition methods are provided for antagonizing the action of an a4-integrin to treat various pathophysiological conditions.